

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number
WO 2021/255137 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:
PCT/EP2021/066335

(22) International Filing Date:
17 June 2021 (17.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20181072.8 19 June 2020 (19.06.2020) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BRUENKER, Peter**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **CARPY GUTIERREZ CIRLOS, Alejandro**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **FREIMOSER-GRUNDSCHOBBER, Anne**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **GEIGER, Martina**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **HOFFER, Thomas**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **KLEIN, Christian**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **MOESSNER, Ekkehard**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **NEUMANN, Christiane**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **BUSER, Andres**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES

(57) Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idio-type-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idio-type-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idio-type-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idio-type-specific polypeptides in the treatment of disease.

WO 2021/255137 A1